A recent article published in Brain proposes a clinical method for subtyping Parkinson disease cases on an individual basis, with implications for better patient stratification for personalized medicine. The authors report biological validity in terms of imaging and cerebrospinal fluid parameters, but long-term predictive validity remains to be established.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson’s disease
npj Parkinson's Disease Open Access 02 August 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Foltynie, T., Brayne, C. & Barker, R. A. The heterogeneity of idiopathic Parkinson's disease. J. Neurol. 249, 138–145 (2002).
Fereshtehnejad, S. M., Zeighami, Y., Dagher, A. & Postuma, R. B. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain http://dx.doi.org/10.1093/brain/awx118 (2017).
Lewis, S. J. et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J. Neurol. Neurosurg. Psychiatry 76, 343–348 (2005).
van Rooden, S. M. et al. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov. Disord. 25, 969–978 (2010).
Graham, J. M. & Sagar, H. J. A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov. Disord. 14, 10–20 (1999).
Erro, R. et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat. Disord. 28, 137–140 (2016).
Foltynie, T., Brayne, C. E., Robbins, T. W. & Barker, R. A. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127, 550–560 (2004).
Collins, L. M. & Williams-Gray, C. H. The genetic basis of cognitive impairment and dementia in Parkinson's disease. Front. Psychiatry 7, 89 (2016).
Velseboer, D. C. et al. Development and external validation of a prognostic model in newly diagnosed Parkinson disease. Neurology 86, 986–993 (2016).
Liu, G. et al. Prediction of cognition in Parkinson's disease with a clinical–genetic score: longitudinal analysis of nine cohorts. Lancet Neurol. http://dx.doi.org/10.1016/S1474-4422(17)30122-9 (2017).
Acknowledgements
The work of the authors is supported by the NIHR Cambridge Biomedical Research Centre and the Wellcome Trust–Medical Research Council Cambridge Stem Cell Institute.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Williams-Gray, C., Barker, R. Defining PD subtypes — a step toward personalized management?. Nat Rev Neurol 13, 454–455 (2017). https://doi.org/10.1038/nrneurol.2017.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.98
This article is cited by
-
Clinical classification systems and long-term outcome in mid- and late-stage Parkinson’s disease
npj Parkinson's Disease (2021)
-
Two-Way Horizontal and Vertical Omics Integration for Disease Subtype Discovery
Statistics in Biosciences (2020)